Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ludwig Oxford’s newest recruit is interviewed in the latest edition of the Ludwig Link.

Professor Yang Shi joined the Oxford Branch of the Ludwig Institute for Cancer Research in the summer of 2020. His research focuses on applying his extensive fundamental knowledge of epigenetic regulators to cancer. In particular, the Shi lab is studying the role of epigenetics in acute myeloid leukaemia and glioma, in addition to identifying epigenetic regulators that can increase the efficacy of immune checkpoint blockade therapy.

In this interview, Yang talks about why he decided to move to Oxford, his research aims at the Branch and what he likes most about his career in research.

Read the full interview on the Ludwig Cancer Research website.

Similar stories

Two new therapeutic targets in tuft cell-like small cell lung cancer

Yang Shi’s group identify two transcriptional co-activators that are selectively important for cancer cell but not normal cell survival.

Ludwig Oxford's Yang Shi elected to National Academy of Medicine

Ludwig Cancer Research congratulates Yang Shi on one of the highest honours in the fields of health and medicine